Involvement of c-Jun N-terminal kinase in reversal of multidrug resistance of human leukemia cells in hypoxia by 5-bromotetrandrine

References

• Chen H, Bi W, Cao B, et al. A novel podophyllotoxin derivative (YB-1EPN) induces apoptosis and down-regulates express of P-glycoprotein in multidrug resistance cell line KBV200. Eur J Pharmacol. 2010;627:69–74.
   PubMed Web of Science ®Google Scholar
• Sipos G, Kuchler K. Fungal ATP-binding cassette (ABC) transporters in drug resistance and detoxification. Curr Drug Targets. 2006;7: 471–481.
   PubMed Web of Science ®Google Scholar
• Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 2006;580:2903–2909.
   PubMed Web of Science ®Google Scholar
• Raguz S, Tamburo De Bella M, et al. Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. Clin Cancer Res 2004;10:2776–2783.
   PubMed Web of Science ®Google Scholar
• Zhou J, Liu M, Aneja R, et al. Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res 2006;66:445–452.
   PubMed Web of Science ®Google Scholar
• Liu M, Li DW, Aneja R, et al. PO2-dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun NH2-terminal kinase pathway. J Biol Chem 2007;282:17581–17586.
   PubMed Web of Science ®Google Scholar
• Katrina M. Comerford, Eoin P. Cummins, Cormac T. Taylor, et al. c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1α-dependent P-glycoprotein expression in hypoxia. Cancer Res 2004;64:9057–9061.
   PubMed Web of Science ®Google Scholar
• Comerford KM, Wallace TJ, Karhausen J, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62:3387–3394.
   PubMed Web of Science ®Google Scholar
• Wartenberg M, Ling FC, Muschen M, et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor 1(HIF-1) and reactive oxygen species. FASEB J 2003;17:503–505.
   PubMed Web of Science ®Google Scholar
• Osborn MT, Chambers TC. Role of the stress-activated/c-Jun NH2-terminal kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem 1996;271:30950–30955.
   PubMed Web of Science ®Google Scholar
• Juneja J, Casey PJ. G12 signaling through c-Jun NH2-terminal kinase promotes breast cancer cell invasion. PloS One. 2011;6:1–8.
   Web of Science ®Google Scholar
• Gupta S, Barrett T, Whitmarsh AJ, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996;15:2760–2770.
   PubMed Web of Science ®Google Scholar
• Frolova O, Samudio I, Benito JM, et al. Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther 2012;13:858–870.
   PubMed Web of Science ®Google Scholar
• Ledoux S, Yang R, Friedlander G, et al. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res 2003;63:7284–7290.
   PubMed Web of Science ®Google Scholar
• Comerford KM, Cummins EP, Taylor CT. c-Jun NH2- terminal kinase activation contributes to hypoxia inducible factor 1a-dependent P-glycoprotein expression in hypoxia. Cancer Res 2004;64:9057–9061.
   PubMed Web of Science ®Google Scholar
• Jin J, Wang FP, Wei HL, et al. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-BrTet. Cancer Chemother Pharmacol 2005;55,179–188.
   PubMed Web of Science ®Google Scholar
• Wang FP, Wang L, Yang JS, et al. Reversal of P-glycoprotein-dependent resistance to vinblastine by newly synthesized bisbenzylisoquinoline alkaloids in mouse leukemia P388 cells. Biol Pharm Bull 2005;28:1979–1982.
   PubMed Web of Science ®Google Scholar
• Zheng L, Qing YP, Xu N, et al. Pharmacokinetics and safety of bromotetrandrine (BrTet, W198) after single-dose intravenous administration in healthy Chinese volunteers. J Clin Pharm Ther 2010;35:113–119.
   PubMed Web of Science ®Google Scholar
• Liu XD, Sun H, Liu GT. 5-Bromotetrandrine enhances the sensitivity of doxorubicin-induced apoptosis in intrinsic resistant human hepatic cancer Bel7402 cells. Cancer Lett 2010;292:24–31.
   PubMed Web of Science ®Google Scholar
• Li G, Xiang Y, Sabapathy K, et al. An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase. J Biol Chem 2004;279:1123–1131.
   PubMed Web of Science ®Google Scholar
• Jin J, Mullen TD, Hou Q, et al. AMPK inhibitor compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells. J Lipid Res 2009;50:2389–2397.
   PubMed Web of Science ®Google Scholar
• Juneja J, Cushman I, Casey PJ. G12 signaling through c-Jun NH2-terminal kinase promotes breast cancer cell invasion. PLoS One 2011;6:e26085.
   PubMed Web of Science ®Google Scholar
• Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002;10:584–592.
   Web of Science ®Google Scholar
• Tidefelt U, Liliemark J, Gruber A, et al. P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J Clin Oncol 2000;18:1837–1844.
   PubMed Web of Science ®Google Scholar
• Miao ZH, Ding J. Transcription factor c-Jun activation represses mdr-1 gene expression. Cancer Res 2003;63:4527–4532.
   PubMed Web of Science ®Google Scholar
• Cheng J, Wu WW, Chen BA, et al. Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells. Int J Nanomed 2009:4:209–216.
   PubMed Web of Science ®Google Scholar
• Alfranca A, Gutierrez MD, Vara A, et al. c-Jun and hypoxia-inducible factor 1 functionally cooperate in hypoxia-induced gene transcription. Mol Cell Biol 2002;22:12–22.
   PubMed Web of Science ®Google Scholar
• Poulaki V, Mitsiades CS, McMullan C, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab 2003;88:5392–5398.
   PubMed Web of Science ®Google Scholar
• Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 2006;13:739–749.
   PubMed Web of Science ®Google Scholar
• Sui H, Wang Y, Liu X, et al. COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis 2011;32:667–675.
   PubMed Web of Science ®Google Scholar
• Mechta-Grigoriou F, Gerald D, Yaniv M. The mammalian Jun proteins: redundancy and specificity. Oncogene 2001;20:2378–2389.
   PubMed Web of Science ®Google Scholar
• Shaulian E, Karin M. AP1 in cell proliferation and survival. Oncogene 2001;20:2390–2400.
   PubMed Web of Science ®Google Scholar
• Lock-Andersen J, Horn J, Sjostrand H. [Prognosis after sentinel node biopsy in malignant melanoma]. Ugeskrift Laeger 2006;168:2457–2462.
   PubMedGoogle Scholar
• Eberle J, Kurbanov BM, Hossini AM, et al. Overcoming apoptosis deficiency of melanoma--hope for new therapeutic approaches. Drug Resist Updat 2007;10:218–234.
   PubMed Web of Science ®Google Scholar
• Miao ZH, Tang T, Zhang YX, et al. Cytotoxicity and apoptosis induction by the anti-topoisomerase II agent, salvicine, associated with downregulating P-glycoprotein expression in multidrug-resistant cells. Int J Cancer 2003;106:108–115.
   PubMed Web of Science ®Google Scholar
• Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001;98:2603–2614.
   PubMed Web of Science ®Google Scholar
• Fan M, Goodwin M, Vu T, et al. Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J Biol Chem 2000;275:29980–29985.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Krasovskis E, Sutton VR, et al. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 1998;95:7024–7029.
   PubMed Web of Science ®Google Scholar
• Ruefli AA, Smyth MJ, Johnstone RW. HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood 2000;95: 2378–2385.
   PubMed Web of Science ®Google Scholar